Search In this Thesis
   Search In this Thesis  
العنوان
Evaluation of chemotherapy service at the alexandria university clinical oncology department in view of international recommendations/
المؤلف
Ojiwa, Regina Nanzia.
هيئة الاعداد
باحث / ريجينا نانزيا أوجاوا
مشرف / أشرف محمود الإنبابي
مشرف / شريف فاروق الزواوي
مناقش / عبدالعزيز مأمون بلال
الموضوع
Clinical Oncology. Nuclear Medicine.
تاريخ النشر
2021.
عدد الصفحات
52 p. :
اللغة
الإنجليزية
الدرجة
ماجستير
التخصص
علم الأورام
تاريخ الإجازة
26/6/2021
مكان الإجازة
جامعة الاسكندريه - كلية الطب - Clinical Oncology and Nuclear Medicine
الفهرس
Only 14 pages are availabe for public view

from 65

from 65

Abstract

Chemotherapy is considered the most commonly used modality in the current management of adult oncology patients. In some cases it is given in combination with other treatment modalities such as radiotherapy, surgery, hormonal and targeted therapy.
The aim of this study was to assess the aspects of chemotherapy service in the clinical oncology department Alexandria university hospital, to come up with recommendations and a chemotherapy checklist to facilitate the chemotherapy process.
This was a prospective study conducted on 300 adult patients seen from August 2019 to February 2020. The patients’ demographic data, clinical details and chemotherapy data were collected and analyzed using SPSS version 2.
The median age was 54 years old with a range of 17-83 years. 71.3% of the patients were overweight & obese. Breast cancer accounted for 24.3% of the cases, ovarian (6.7%) and colon/lung cancer (5.7%) each. Adriamycin/cyclophosphamide followed by Taxol was the most commonly used regimen (17.3%), followed by Paclitaxel/Carboplatin (13%) and Gemcitabine/Cisplatin (7%). Majority of the patients were on outpatient chemotherapy (77%) and 23% were inpatients. A small percentage of patients (5.7%) received target therapy. 82% of patients were on intravenous chemotherapy and 6.3% on oral chemotherapy. 100% of the patients gave verbal consent before the start of treatment. 21% of the patients had dose modifications during their treatment cycle due to hematological toxicity (17.3%), neurological toxicity (3%) and renal impairment (1%). 1.3% of the patients died before completion of their treatment due to disease progression. There was a statistical significant correlation between the hematological toxicity and treatment duration (p=0.002) and neurological toxicity with treatment duration (p=0.016). Moreover there was a correlation between BMI and breast cancer, ovarian cancer, nasopharyngeal cancer, esophageal cancer, hepatocellular carcinoma and neuroendocrine tumor
Chemotherapy is considered the most commonly used modality in the current management of adult oncology patients. In some cases it is given in combination with other treatment modalities such as radiotherapy, surgery, hormonal and targeted therapy.
The aim of this study was to assess the aspects of chemotherapy service in the clinical oncology department Alexandria university hospital, to come up with recommendations and a chemotherapy checklist to facilitate the chemotherapy process.
This was a prospective study conducted on 300 adult patients seen from August 2019 to February 2020. The patients’ demographic data, clinical details and chemotherapy data were collected and analyzed using SPSS version 2.
The median age was 54 years old with a range of 17-83 years. 71.3% of the patients were overweight & obese. Breast cancer accounted for 24.3% of the cases, ovarian (6.7%) and colon/lung cancer (5.7%) each. Adriamycin/cyclophosphamide followed by Taxol was the most commonly used regimen (17.3%), followed by Paclitaxel/Carboplatin (13%) and Gemcitabine/Cisplatin (7%). Majority of the patients were on outpatient chemotherapy (77%) and 23% were inpatients. A small percentage of patients (5.7%) received target therapy. 82% of patients were on intravenous chemotherapy and 6.3% on oral chemotherapy. 100% of the patients gave verbal consent before the start of treatment. 21% of the patients had dose modifications during their treatment cycle due to hematological toxicity (17.3%), neurological toxicity (3%) and renal impairment (1%). 1.3% of the patients died before completion of their treatment due to disease progression. There was a statistical significant correlation between the hematological toxicity and treatment duration (p=0.002) and neurological toxicity with treatment duration (p=0.016). Moreover there was a correlation between BMI and breast cancer, ovarian cancer, nasopharyngeal cancer, esophageal cancer, hepatocellular carcinoma and neuroendocrine tumor